RxDoctor Payments Data
★ My doctorsLook up a doctor →

Rose Pitt

Psychiatry · Tustin, CANPI 1841397700

Payments from drug & device makers

$4,404in general payments, 2019–2025

Across 241 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Bausch Health US, LLC$1K
  • Neurocrine Biosciences, Inc.$293
  • Ironshore Pharmaceuticals Inc.$284
  • Corium, LLC$228
  • Otsuka America Pharmaceutical, Inc.$219
  • plus $826 from 14 others

What the payments were for

  • Food & beverage$4,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)55$1,281
Bausch Health US, LLC95$1,272
Neurocrine Biosciences, Inc.11$293
Ironshore Pharmaceuticals Inc.15$284
Corium, LLC12$228
Otsuka America Pharmaceutical, Inc.10$219
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$195
Takeda Pharmaceuticals U.S.A., Inc.7$152
Sunovion Pharmaceuticals Inc.6$85
Lundbeck LLC4$63
Vanda Pharmaceuticals Inc.3$58
Teva Pharmaceuticals USA, Inc.2$48
Brainsway USA Inc1$37
Jazz Pharmaceuticals Inc.2$36
Adlon Therapeutics L.p.2$34
Eisai Inc.2$32
Tris Pharma Inc2$29
Supernus Pharmaceuticals, Inc.2$26
Collegium Pharmaceutical, Inc.1$17
Arbor Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,404 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide21$17,380
Lurasidone Hcl25$2,281
Fluvoxamine Maleate ErFluvoxamine Maleate11$2,263
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$1,784
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine36$1,230
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$1,204
Clonazepam46$941
Bupropion XlBupropion Hcl28$797
Lamotrigine35$670
Escitalopram Oxalate21$338
Alprazolam46$201
Gabapentin16$188
Sertraline Hcl14$154
Lorazepam23$135
Zolpidem Tartrate23$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$152$17,38021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Tustin

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →